

Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs
Novartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.

Healthcare Leadership Strategies to Prevent Workplace Violence
Workers deserve environments that protect their well-being, and patients deserve care from professionals who aren’t operating in fear.

Beyond Politics: Payer Solutions for Fluoride-free Communities
This isn’t a political issue, it’s a public health challenge with real consequences for kids’ futures. As reality sets in, we must face the possibility of a post-fluoridation era and find new ways to give kids in at-risk communities a fair shot at a healthy smile.